Navigation Links
IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board
Date:3/14/2017

BRANFORD, Conn., March 14, 2017 /PRNewswire-USNewswire/ -- IsoPlexis Corporation (IsoPlexis), a venture capital-funded life sciences company dedicated to accelerating the fight against cancer, autoimmune disease, infectious disease and more through a precision single-cell detection platform, today announced the appointment of Dr. David Ho to its Scientific Advisory Board. Dr. Ho is a recognized pioneer in the infectious disease area. He has authored more than 400 publications, was named Time magazine's 1996 Man of the Year for his pioneering work in AIDS research and is the recipient of 12 honorary doctorates for his scientific contributions.

IsoPlexis Chief Executive Officer Sean Mackay said, "Dr. David Ho is a critical addition to our Scientific Advisory Board. As we venture into broader applications in infectious disease and beyond, his position as a thought leading scientist will help us to accelerate efforts to combat these diseases."

IsoPlexis Scientific Advisory Board Chair Dr. Rong Fan, an associate professor of Biomedical Engineering at Yale, added, "With Dr. Ho, our scientific board has added a truly eminent scientist with proven success in harnessing the power of immunology to address life-threatening diseases and ailments."

Dr. David Ho is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center. His lab helped pioneer the field of quantitation of HIV among infected individuals. In the last decade, his research team extended this work and revolutionized the paradigm for AIDS pathogenesis by demonstrating the highly dynamic nature of HIV replication in vivo. Their groundbreaking studies on HIV dynamics formed the foundation for combination antiretroviral therapy, which Dr. Ho also helped to champion. Such a treatment approach has transformed HIV from a death sentence to a manageable disease, and is now being applied widely throughout the developing world.

Dr. David Ho said, "I am excited to join IsoPlexis as a Scientific Advisory Board member. By merging the top minds in engineering with leading researchers and clinicians, IsoPlexis is able to offer breakthrough clinical insights. As the company's applications expand, it has the potential to make significant progress on critical detection issues, enabling the advancement of various immune therapies."

ABOUT ISOPLEXIS:
IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Cal Tech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isoplexis-adds-infectious-disease-pioneer-dr-david-ho-to-its-scientific-advisory-board-300422907.html


'/>"/>
SOURCE IsoPlexis Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
2. Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc.
3. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
4. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
5. Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
6. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
7. Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
8. Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
9. Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019
10. Edison Nation Medical Announces Open Innovation Search Focused on Preventing Spread and Transmission of Infectious Disease
11. Symbiotix Biotherapies Announces $2.3 Million Award from NIHs National Institute of Allergy and Infectious Diseases (NIAID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)...  Exactly 50 years ago today, the Monterey Pop Festival ... as the San Francisco "Summer of Love."  To celebrate the ... innovations in strategic market research portals that it will begin ... of Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/27/2017)... and London UK (PRWEB) , ... June 27, 2017 , ... ... to a clinical study is whether they can trust the sponsor to pay them ... is vital that sponsors and CROs establish payment strategies that encourage sites to work ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, ... event was held in Syracuse, New York, where EarQ is headquartered. , Together, ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... of Atmosera Managed Azure Services . The trusted, transparent, and secure solution ... the company’s growing customer base. Atmosera’s next generation services include integrated capabilities for ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... ... orthodontic treatments . Orthodontics is a dental specialty that focuses on treating alignment ... Benefits include improved aesthetics and function. , North Hollywood dentist , ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... & Sexual Medicine Specialists, in collaboration with the Fertility Center of California, is ... care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These ...
Breaking Medicine News(10 mins):